Page last updated: 2024-09-02

pyronaridine and ddd107498

pyronaridine has been researched along with ddd107498 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Avery, VM; BaragaƱa, B; Campbell, SF; Delves, MJ; Duffy, S; Fairlamb, AH; Frearson, JA; Gilbert, IH; Gray, DW; Grimaldi, R; Hallyburton, I; Meister, S; Norcross, NR; Norval, S; Osuna-Cabello, M; Porzelle, A; Read, KD; Riley, J; Simeons, FR; Sinden, RE; Stojanovski, L; Waterson, D; Willis, P; Wilson, C; Winzeler, EA; Wittlin, S; Wyatt, PG1
Badolo, L; Dhingra, SK; Fidock, DA; Giddins, MJ; Greco, B; Gumpp, C; Jonat, B; Oeuvray, C; Rottmann, M; Spangenberg, T; Yin, X1

Other Studies

2 other study(ies) available for pyronaridine and ddd107498

ArticleYear
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
    Journal of medicinal chemistry, 2016, 11-10, Volume: 59, Issue:21

    Topics: Animals; Antimalarials; Disease Models, Animal; Drug Discovery; Malaria; Mice; Molecular Structure; Plasmodium falciparum; Quinolines; Structure-Activity Relationship

2016
Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor.
    Antimicrobial agents and chemotherapy, 2020, 03-24, Volume: 64, Issue:4

    Topics: Animals; Antimalarials; Drug Resistance; Drug Therapy, Combination; Hemeproteins; Malaria, Falciparum; Mice; Mice, SCID; Naphthyridines; Peptide Elongation Factor 2; Plasmodium falciparum; Quinolines

2020